AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home iLABMED Article
PDF (650.3 KB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Commentary | Open Access

Interim proposal for collecting and handling of microbiology specimens from patients with COVID‐19 in general hospitals

Zhaofang Jiang1, Shan Chen1, Jiayao Qu1, Siyuan Liu2, Tao Hong3, Houming Liu1, Yi‐Wei Tang2, Jiuxin Qu1( ), Hongzhou Lu1( )
Department of Clinical Laboratory, Shenzhen Third People's Hospital, Southern University of Science and Technology, National Clinical Research Center for Infectious Diseases, Shenzhen, Guangdong, China
Department of Medical Affairs, Danaher/Cepheid China, Shanghai, China
Department of Pathology, Rhode Island Hospital, Providence, Rhode Island, USA

Zhaofang Jiang and Shan Chen contributed equally to this work.

Show Author Information

Graphical Abstract

Keywords

biosafetyCOVID‐19microbiology specimensSARS‐CoV‐2

References

[1]

Mohsin M, Mahmud S. Omicron SARS‐CoV‐2 variant of concern: a review on its transmissibility, immune evasion, reinfection, and severity. Medicine (Baltim). 2022;101(19): e29165. https://doi.org/10.1097/MD.0000000000029165
Crossref Google Scholar
[2]

Landis BC, Brooks AE, Digre KB, Seay MD. Coronavirus disease 2019, eye pain, headache, and beyond. J Neuro Ophthalmol. 2022;42(1): 18–25. https://doi.org/10.1097/WNO.0000000000001526
Crossref Google Scholar
[3]

Tian D, Sun Y, Xu H, Ye Q. The emergence and epidemic characteristics of the highly mutated SARS‐CoV‐2 Omicron variant. J Med Virol. 2022;94(6): 2376–83. https://doi.org/10.1002/jmv.27643
Crossref Google Scholar
[4]

Callaway E. Heavily mutated Omicron variant puts scientists on alert. Nature. 2021;600(7887): 21. https://doi.org/10.1038/d41586‐021‐03552‐w
Crossref Google Scholar
[5]
CDC. COVID data tracker. Centers for Disease Control and Prevention; 2020. https://covid.cdc.gov/covid‐data‐tracker/#datatracker‐home. Accessed 13 January 2022.
[6]

Collie S, Champion J, Moultrie H, Bekker LG, Gray G. Effectiveness of BNT162b2 vaccine against Omicron variant in South Africa. N Engl J Med. 2022;386(5): 494–6. https://doi.org/10.1056/NEJMc2119270
Crossref Google Scholar
[7]

Jung C, Kmiec D, Koepke L, Zech F, Jacob T, Sparrer KMJ, et al. Omicron: What makes the latest SARS‐CoV‐2 variant of concern so concerning? J Virol. 2022;96(6): e0207721. https://doi.org/10.1128/jvi.02077‐21
Crossref Google Scholar
[8]

Guo Y, Han J, Zhang Y, He J, Yu W, Zhang X, et al. SARS‐CoV‐2 Omicron variant: epidemiological features, biological characteristics, and clinical significance. Front Immunol. 2022;13: 877101. https://doi.org/10.3389/fimmu.2022.877101
Crossref Google Scholar
[9]

Xu A, Hong B, Lou F, Wang S, Li W, Shafqat A, et al. Sub‐lineages of the SARS‐CoV‐2 Omicron variants: characteristics and prevention. MedComm. 2022;3(3): e172. https://doi.org/10.1002/mco2.172
Crossref Google Scholar
[10]

Kupferschmidt K, Vogel G. Omicron threat remains fuzzy as cases explode. Science. 2022;375(6576): 9–10. https://doi.org/10.1126/science.acz9928
Crossref Google Scholar
[11]

Markovskaya Y, Gavioli EM, Cusumano JA, Glatt AE. Coronavirus disease 2019 (COVID‐19): secondary bacterial infections and the impact on antimicrobial resistance during the COVID‐19 pandemic. Antimicrob Steward Healthc Epidemiol. 2022;2(1): e114. https://doi.org/10.1017/ash.2022.253
Crossref Google Scholar
[12]

Hoenigl M, Seidel D, Sprute R, Cunha C, Oliverio M, Goldman GH, et al. COVID‐19‐associated fungal infections. Nat Microbiol. 2022;7(8): 1127–40. https://doi.org/10.1038/s41564‐022‐01172‐2
Crossref Google Scholar
[13]

Mina S, Yaakoub H, Annweiler C, Dubée V, Papon N. COVID‐19 and Fungal infections: a double debacle. Microb Infect. 2022;24(8): 105039. https://doi.org/10.1016/j.micinf.2022.105039
Crossref Google Scholar
[14]
National Health Commission of the People’s Republic of China. Technical guidelines for specimen collection and detection of SARS‐CoV‐2[S]; 2022. http://www.nhc.gov.cn
[15]
pecimens for COVID‐19 Testing[EB/OL]. https://www.cdc. gov/coronavirus/2019‐ncov/lab/guidelines‐clinical‐specimens.html
[16]

Dinnes J, Sharma P, Berhane S, van Wyk SS, Nyaaba N, Domen J, et al. Cochrane COVID‐19 Diagnostic Test Accuracy Group. Rapid, point‐of‐care antigen tests for diagnosis of SARS‐CoV‐2 infection. Cochrane Database Syst Rev. 2022;7(7):CD013705. https://doi.org/10.1002/14651858.CD013705.pub3
Crossref Google Scholar
[17]

Meng Z, Guo S, Zhou Y, Li M, Wang M, Ying B. Applications of laboratory findings in the prevention, diagnosis, treatment, and monitoring of COVID‐19. Signal Transduct Targeted Ther. 2021;6(1):316. https://doi.org/10.1038/s41392‐021‐00731‐z
Crossref Google Scholar
[18]

Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. China medical treatment expert group for covid‐19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20. https://doi.org/10.1056/NEJMoa2002032
Crossref Google Scholar
[19]

Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID‐19): a review. JAMA. 2020;324(8):782–93. https://doi.org/10.1001/jama.2020.12839
Crossref Google Scholar
iLABMED
Volume 1 Issue 1,
June 2023
Pages 15-21
DOI: 10.1002/ila2.13
Cite this article:
Jiang Z, Chen S, Qu J, et al. Interim proposal for collecting and handling of microbiology specimens from patients with COVID‐19 in general hospitals. iLABMED, 2023, 1(1): 15-21. https://doi.org/10.1002/ila2.13

783

Views

65

Downloads

0

Crossref

Altmetrics
Published: 29 May 2023
© 2023 The Authors. Tsinghua University Press.

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
Return